← Back to Search

Immunomodulatory agent

Iberdomide Powder (Fasted), followed by Iberdomide Capsule (Fasted) for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 72 hours post-dose for period 1 and period 2 (each period is 4 days, with a 5-9 day washout between each dose)

Awards & highlights

Study Summary

This trial tests how well a new drug powder works and if food affects how fast it works in healthy adults.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 72 hours post-dose for period 1 and period 2 (each period is 4 days, with a 5-9 day washout between each dose)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 72 hours post-dose for period 1 and period 2 (each period is 4 days, with a 5-9 day washout between each dose)

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 hours post-dose for period 1 and period 2 (each period is 4 days, with a 5-9 day washout between each dose) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF))

Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T))

Maximum Observed Plasma Concentration (Cmax)

Secondary outcome measures

Number of Participants with Adverse Events

Number of Participants with Clinical Laboratory Abnormalities

Number of Participants with Electrocardiogram Abnormalities

+2 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: Iberdomide Powder (Fed), followed by Iberdomide Powder (Fasted)Experimental Treatment1 Intervention

Group II: Iberdomide Powder (Fasted), followed by Iberdomide Powder (Fed)Experimental Treatment1 Intervention

Group III: Iberdomide Powder (Fasted), followed by Iberdomide Capsule (Fasted)Experimental Treatment1 Intervention

Group IV: Iberdomide Capsule (Fasted), followed by Iberdomide Powder (Fasted)Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Iberdomide

2021

Completed Phase 1

~60

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,482 Total Patients Enrolled

CelgeneIndustry Sponsor

636 Previous Clinical Trials

128,939 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the criteria for qualifying to participate in this trial?

"To be part of this medical trial, potential subjects must meet a certain set of criteria including good health and age between 18 to 65 years old. In total, 32 individuals will participate in the experiment."

Answered by AI

Are persons aged twenty or more eligible for this investigation?

"The age criteria for this study requires all participants to be aged between 18 and 65 years."

Answered by AI

How detrimental is it to ingest Iberdomide Powder (Fasted), followed by Iberdomide Capsule (Fasted) for humans?

"The available evidence suggests that Iberdomide Powder (Fasted) and then Iberdomide Capsule (Fasted) are relatively safe, thus both received a score of 1 on our safety scale. This is due to this being an early phase trial with limited data regarding efficacy or safety outcomes."

Answered by AI

What is the uppermost capacity of participants in this experiment?

"Affirmative. As indicated on clinicaltrials.gov, this research endeavor is currently enrolling individuals to participate in the study and was last updated as recently as June 9th 2023. The trial seeks 32 participants from a single center."

Answered by AI

Is enrollment for this clinical trial still open to participants?

"Affirmative. Based on the information published by clinicaltrials.gov, this research venture is currently in need of volunteers. It was first posted on May 18th 2023 and its most recent update dates back to June 9th 2023; 32 individuals are sought from one medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

2023. "A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05899738.